Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Regulatory Perspectives on Pharmacogenomics

It is well known that there is a major problem in the health care system in the United States related to providing new drugs that are effective and relatively safe in a wide diversity of patients with undifferentiated diseases whose individual dose-response relationship varies based on genetic, disease, environmental, and life-style factors. While many may argue over [Pg.265]

Variability in drug response is a major barrier to successful drug development. As Sir William Osier said in 1892 about the practice of medicine, if it were not for the great variability among individuals, medicine might as well be a science and not an art. PGx can provide the scientific tools that enable us to explore the pathophysiological mechanisms for these differences in drug response at [Pg.267]

Regulatory Perspectives on Pharmacogenetics and Pharmacogenomics 11.8.1 Safe Harbor... [Pg.219]

See other pages where Regulatory Perspectives on Pharmacogenomics is mentioned: [Pg.265]    [Pg.265]    [Pg.267]    [Pg.269]    [Pg.271]    [Pg.273]    [Pg.275]    [Pg.277]    [Pg.279]    [Pg.281]    [Pg.283]    [Pg.285]    [Pg.658]    [Pg.251]    [Pg.265]    [Pg.265]    [Pg.267]    [Pg.269]    [Pg.271]    [Pg.273]    [Pg.275]    [Pg.277]    [Pg.279]    [Pg.281]    [Pg.283]    [Pg.285]    [Pg.658]    [Pg.251]    [Pg.201]    [Pg.270]    [Pg.330]    [Pg.260]   


SEARCH



Pharmacogenomic

Pharmacogenomics

© 2024 chempedia.info